| The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy U Sengupta, AN Nilson, R Kayed EBioMedicine 6, 42-49, 2016 | 717 | 2016 |
| Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases AN Nilson, KC English, JE Gerson, T Barton Whittle, C Nicolas Crain, ... Journal of Alzheimer's Disease 55 (3), 1083-1099, 2017 | 164 | 2017 |
| Cerebral microvascular accumulation of tau oligomers in Alzheimer’s disease and related tauopathies DL Castillo-Carranza, AN Nilson, CE Van Skike, JB Jahrling, K Patel, ... Aging and disease 8 (3), 257, 2017 | 100 | 2017 |
| The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6: 42–49 U Sengupta, AN Nilson, R Kayed | 45 | 2016 |
| The Role of Amyloid-beta Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine. 2016; 6: 42–9 U Sengupta, AN Nilson, R Kayed Epub 2016/05/24. https://doi. org/10.1016/j. ebiom. 2016. 03.035 PMID: 27211547, 0 | 17 | |
| G Protein Biased Signaling by Non‐catechol Dopamine D1 Receptor Agonists AN Nilson, P Wang, MK Jain, J Zhou, JA Allen The FASEB Journal 34 (S1), 1-1, 2020 | 2 | 2020 |
| Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical … RB Free, AN Nilson, NM Boldizsar, TB Doyle, RM Rodriguiz, ... ACS Pharmacology & Translational Science 6 (1), 151-170, 2022 | 1 | 2022 |
| Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders AN Nilson, DE Felsing, JA Allen GPCRs as Therapeutic Targets 2, 677-731, 2022 | 1 | 2022 |
| β‐arrestins mediate rapid 5‐HT2A receptor endocytosis to regulate intensity and duration of signaling DE Felsing, A Nilson, M Jain, S Raval, A Inoue, J Allen The FASEB Journal 33 (S1), 502.3-502.3, 2019 | 1 | 2019 |
| Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder CA Boateng, AN Nilson, R Placide, ML Pham, FM Jakobs, N Boldizsar, ... Journal of Medicinal Chemistry 66 (17), 12141-12162, 2023 | | 2023 |
| Dopamine receptor divergence revealed using a common ligand DR Sibley, AN Nilson, AE Moritz, L Shi Trends in Pharmacological Sciences, 2023 | | 2023 |
| Bioisosteric Replacement of Amides Linkers with 1, 2, 3-Triazoles for Improved Pharmacokinetics Without Losing Dopamine D4 Receptor Potency or Selectivity D Panasis, M Alkhatib, J Saez, J Hanson, AN Nilson, FM Jacobs, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| Optimization of a Novel D2 Dopamine Receptor-Selective Antagonist into Lead Candidates for the Treatment of Neuropsychiatric Disorders A Nilson, J Hanson, AE Dulcey, X Wen, RB Free, RR Calvo, JJ Marugan, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| β-Arrestins Mediate Rapid 5-HT2A Receptor Endocytosis to Control the Efficacy and Kinetics of Serotonin and Psychedelic Hallucinogen Signaling H Smith, DE Felsing, A Nilson, JA Allen Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| Substituted Benzothiazole Analogues as Dopamine D4 Receptor Selective Ligands to Treat Substance Use Disorder C Boateng, A Nilson, F Jakobs, RB Free, D Sibley, R Rais, B Slusher, ... NEUROPSYCHOPHARMACOLOGY 47, 418-418, 2022 | | 2022 |
| GPCRs as Therapeutic Targets: Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders AN Nilson, D Felsing, J Allen John Wiley and Sons, 2022 | | 2022 |
| Pharmacology and Therapeutic Potential of Dopamine D4 Receptor Antagonists for Cocaine Use Disorder CA Boateng, AN Nilson, R Placide, ML Pham, FM Jakobs, N Boldizsar, ... | | 2022 |
| Characterization and Chemical Optimization of the D2 Dopamine Receptor‐Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric … AN Nilson, A Dulcey Garcia, RB Free, N Boldizsar, H Pearlstein, ... The FASEB Journal 36, 2022 | | 2022 |
| Novel Dopamine D4 Receptor‐Selective Antagonists For Neuropsychiatric Disorders TM Keck, S Kelshikar, N Shah, C McBride, M Ximello Sanchez, D Panasis, ... The FASEB Journal 36, 2022 | | 2022 |
| Pharmacokinetic Assessment of High Affinity D4RSelective Ligands to Attenuate Cocaine Self-Administration C Boateng, I Korankyi, T Keck, RB Free, A Nilson, N Boldizsar, D Sibley, ... NEUROPSYCHOPHARMACOLOGY 46 (SUPPL 1), 390-391, 2021 | | 2021 |
